CME
Cracking the CRS Code in Myeloma: Insights from a Comprehensive Case Review
March 14, 2024
Host: Caitlin Costello, MD Guest: Sagar Lonial, MD, FACP Bispecific antibodies are the newest immunotherapies approved for heavily pretreated relapsed/refractory myeloma, and they are shown to double response rates. Are you ready to use them
Visit Podcast Website
RSS Podcast Feed
Subscribe
Share
Add to MyCast
Gain access to Blubrry tools that help build your podcast, including free podcast stats!